Dong Mengying, Song Mengyang, Liu Jiangen
Department of Cardiology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, 210029, China.
Department of Cardiovascular, The Second Hospital of Jilin University, Changchun, 130000, China.
Eur J Med Res. 2025 Jul 2;30(1):552. doi: 10.1186/s40001-025-02776-0.
Pulmonary arterial hypertension (PAH) is currently an irreversible disease, with many patients eventually progressing to right heart failure, severely affecting their quality of life and posing a life-threatening risk. Percutaneous atrial septostomy was first performed in infants with transposition of the great arteries in 1966. Since then, it has been used as a palliative treatment for patients with end-stage PAH, significantly improving their quality of life and providing a buffer period while waiting for lung transplantation. However, this method does not fundamentally alter the malignant outcomes of patients with PAH. This study reviews the development and evolution of atrial septostomy, summarises various emerging technologies, and systematically explains the mechanisms, efficacy, and prognosis of palliative treatment in patients with PAH. Furthermore, new ideas for this treatment approach are proposed with the hope that it will bring more benefits to patients with PAH in the future and be more fully utilised.
肺动脉高压（PAH）目前是一种不可逆的疾病，许多患者最终会进展为右心衰竭，严重影响他们的生活质量，并构成生命威胁风险。经皮房间隔造口术于1966年首次在患有大动脉转位的婴儿中实施。从那时起，它一直被用作终末期PAH患者的姑息治疗方法，显著改善了他们的生活质量，并在等待肺移植期间提供了一个缓冲期。然而，这种方法并不能从根本上改变PAH患者的恶性结局。本研究回顾了房间隔造口术的发展和演变，总结了各种新兴技术，并系统地解释了PAH患者姑息治疗的机制、疗效和预后。此外，还提出了这种治疗方法的新思路，希望它将来能给PAH患者带来更多益处，并得到更充分的利用。
